Literature DB >> 27245917

External validity of trials should be taken into account before asthma drug candidates reach market authorisation.

Orestis Briasoulis1, Ross Breckenridge2, Andrew Nunn3.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27245917     DOI： 10.1016/S2213-2600(16)30118-7

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN： 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  2 in total

1.  Asthma biologic trial eligibility and real-world outcomes in the United States.

Authors:  Regina W Lam; Jonathan W Inselman; Molly M Jeffery; Jacob T Maddux; Nilay D Shah; Matthew A Rank
Journal:  J Asthma       Date:  2021-12-06

2.  Asthma Patients Who Stop Asthma Biologics Have a Similar Risk of Asthma Exacerbations as Those Who Continue Asthma Biologics.

Authors:  Molly M Jeffery; Jonathan W Inselman; Jacob T Maddux; Regina W Lam; Nilay D Shah; Matthew A Rank
Journal:  J Allergy Clin Immunol Pract       Date:  2021-02-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.